Countervail Corporation


Countervail receives additional $630,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity.

Following successful completion of earlier studies that demonstrated oral galantamine pre-treatment dosing efficacy for improving survival against soman exposure, the National Institutes of Health awarded an additional $630,000 to continue product development under the existing fast track SBIR grant. These funds will be applied to completing the remaining non-GLP studies and initiating the GLP studies required for NDA submission to the FDA.